Samuel H Perkins

US Patent:

7381793, Jun 3, 2008

Filed:

Dec 24, 2003

Appl. No.:

10/744672

Inventors:

Joseph M. Patti - Cumming GA, US
Timothy J. Foster - Dublin, IE
Elisabet Josefsson - Gothenburg, SE
Deidre Ni Eidhin - Dublin, IE
Magnus A. O. Hook - Houston TX, US
Samuel E. Perkins - Houston TX, US

Assignee:

Inhibitex, Inc. - Alpharetta GA
BioResearch Ireland - Dublin
The Texas A&M University System - College Station TX

International Classification:

C07K 1/00

US Classification:

530350, 435975

Abstract:

Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor.

US Patent:

7816494, Oct 19, 2010

Filed:

Aug 24, 2009

Appl. No.:

12/546268

Inventors:

Joseph M. Patti - Cumming GA, US
Timothy J. Foster - Templeogue, IE
Elizabet Joseffson - Gothenburg, SE
Deidre Ni Eidhin - The Coombe, IE
Magnus A. O. Hook - Houston TX, US
Samuel E. Perkins - Houston TX, US

Assignee:

The Texas A&M University System - College Station TX

International Classification:

C07K 1/00

US Classification:

530350, 530810, 530825, 435975

Abstract:

An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of to wounds or biomaterials.

US Patent:

7834151, Nov 16, 2010

Filed:

Aug 24, 2009

Appl. No.:

12/546289

Inventors:

Joseph M. Patti - Cumming GA, US
Timothy J. Foster - Dublin, IE
Elisabet Josefsson - Goteborg, SE
Deidre Ni Eidhin - Dublin, IE
Magnus A. O. Hook - Houston TX, US
Samuel E. Perkins - Houston TX, US

Assignee:

The Texas A&M University System - College Station TX

International Classification:

C07K 1/00

US Classification:

530350, 5303879, 435975

Abstract:

An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of to wounds or biomaterials.

US Patent:

7855272, Dec 21, 2010

Filed:

Aug 24, 2009

Appl. No.:

12/546322

Inventors:

Joseph M. Patti - Cumming GA, US
Timothy J. Foster - Dublin, IE
Elisabet Josefsson - Gothenburg, SE
Deidre Ni Eidhin - Dublin, IE
Magnus A. O. Hook - Houston TX, US
Samuel E. Perkins - Houston TX, US

Assignee:

Bioresearch Ireland - Dublin
The Texas A&M University System - College Station TX

International Classification:

C07K 1/00

US Classification:

530350, 5303879, 435975

Abstract:

An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of to wounds or biomaterials.

US Patent:

20050026170, Feb 3, 2005

Filed:

Dec 24, 2003

Appl. No.:

10/744616

Inventors:

Joseph Patti - Cumming GA, US
Timothy Foster - Templeogue, IE
Elisabet Josefsson - Goteborg, SE
Deidre Eidhin - The Coombe, IE
Magnus Hook - Houston TX, US
Samuel Perkins - Houston TX, US

International Classification:

C12Q001/68
C07K016/40

US Classification:

435006000, 530388100, 530388260

Abstract:

Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD.

US Patent:

6680195, Jan 20, 2004

Filed:

Nov 25, 1998

Appl. No.:

09/200650

Inventors:

Joseph M. Patti - Cumming GA
Timothy J. Foster - Dublin, IE
Elisabet Josefsson - Gothenburg, SE
Deidre Ni Eidhin - Dublin, IE
Magnus A. O. Hook - Houston TX
Samuel E. Perkins - Houston TX

Assignee:

Inhibitex, Inc. - Norcross GA
Bioresearch Ireland - Dublin
The Texas AM University System - College Station TX

International Classification:

C07H 2104

US Classification:

4353201, 536 237

Abstract:

Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor.